twiist Insulin Pump Launches July 7

Sequel Med Tech has officially announced that its highly anticipated twiist insulin pump will be available starting July 7—marking one of the biggest tech product launches in diabetes tech this year.

At launch, twiist will integrate with the Libre 3 Plus CGM, offering users a streamlined experience right out of the gate. But that’s just the beginning. Sequel has already announced plans to bring support for the Eversense 365 later this year, making twiist the first pump to support an implantable CGM. Additionally, the company recently partnered with Abbott to enable future compatibility with its glucose-ketone sensor currently in development, a move that could further enhance closed-loop safety and insights for users.

So what makes twiist so different?

It’s the first FDA-approved insulin pump that allows bolusing directly from a smartwatch, giving users more freedom and discretion. It also features the lowest glucose target available in the U.S. at 87 mg/dL, helping users push for tighter control. A standout feature is the ability to retroactively adjust carb entries, offering a smarter, more forgiving approach to logging meals. And in a first for insulin delivery, twiist includes advanced occlusion detection powered by sound waves, a completely new method to catch insulin delivery issues faster and more accurately.

To learn more about twiist , watch my interview with Sequel Med Tech’s CEO, Alan Lotvin, below.

Stay updated on the latest diabetes tech and news by subscribing to our newsletter. And, if you’re finding value in our content, consider joining Diabetech All Access—our premium membership that unlocks exclusive content and supports our independent journalism.